Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s share price traded up 5.5% during trading on Tuesday . The stock traded as high as $10.03 and last traded at $10.14. 213,351 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 1,411,193 shares. The stock had previously closed at $9.61.
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. William Blair assumed coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating on the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Needham & Company LLC lowered their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada assumed coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.33.
View Our Latest Stock Analysis on OCUL
Ocular Therapeutix Stock Up 3.0%
The company has a debt-to-equity ratio of 0.26, a current ratio of 10.22 and a quick ratio of 10.14. The company has a market capitalization of $1.77 billion, a PE ratio of -9.63 and a beta of 1.43. The business has a 50-day moving average of $8.31 and a 200 day moving average of $7.87.
Insider Transactions at Ocular Therapeutix
In related news, insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the sale, the insider directly owned 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director directly owned 172,704 shares of the company's stock, valued at $1,202,019.84. This represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Insiders sold 29,079 shares of company stock worth $208,739 over the last quarter. 2.30% of the stock is owned by company insiders.
Institutional Investors Weigh In On Ocular Therapeutix
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in Ocular Therapeutix by 4.5% during the first quarter. Rhumbline Advisers now owns 223,115 shares of the biopharmaceutical company's stock valued at $1,635,000 after purchasing an additional 9,514 shares during the period. Caxton Associates LLP purchased a new stake in Ocular Therapeutix during the first quarter valued at approximately $248,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company's stock valued at $686,000 after purchasing an additional 5,156 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Ocular Therapeutix by 44.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after purchasing an additional 1,600,000 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in Ocular Therapeutix during the first quarter valued at approximately $1,011,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Featured Stories
Before you consider Ocular Therapeutix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.
While Ocular Therapeutix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.